Multidrug-Resistant Sepsis: A Critical Healthcare Challenge
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Sepsis globally accounts for an alarming annual toll of 48.9 million cases, resulting in 11 million deaths, and inflicts an economic burden of approximately USD 38 billion on the United States healthcare system. The rise of multidrug-resistant organisms (MDROs) has elevated the urgency surrounding the management of multidrug-resistant (MDR) sepsis, evolving into a critical global health concern. This review aims to provide a comprehensive overview of the current epidemiology of (MDR) sepsis and its associated healthcare challenges, particularly in critically ill hospitalized patients. Highlighted findings demonstrated the complex nature of (MDR) sepsis pathophysiology and the resulting immune responses, which significantly hinder sepsis treatment. Studies also revealed that aging, antibiotic overuse or abuse, inadequate empiric antibiotic therapy, and underlying comorbidities contribute significantly to recurrent sepsis, thereby leading to septic shock, multi-organ failure, and ultimately immune paralysis, which all contribute to high mortality rates among sepsis patients. Moreover, studies confirmed a correlation between elevated readmission rates and an increased risk of cognitive and organ dysfunction among sepsis patients, amplifying hospital-associated costs. To mitigate the impact of sepsis burden, researchers have directed their efforts towards innovative diagnostic methods like point-of-care testing (POCT) devices for rapid, accurate, and particularly bedside detection of sepsis; however, these methods are currently limited to detecting only a few resistance biomarkers, thus warranting further exploration. Numerous interventions have also been introduced to treat MDR sepsis, including combination therapy with antibiotics from two different classes and precision therapy, which involves personalized treatment strategies tailored to individual needs. Finally, addressing MDR-associated healthcare challenges at regional levels based on local pathogen resistance patterns emerges as a critical strategy for effective sepsis treatment and minimizing adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The third international consensus definitions for sepsis and septic shock (Sepsis-3).
Singer, M., Deutschman, C. S., Seymour, C. W., Shankar-Hari, M., Annane, D., Bauer, M., Bellomo, R., Bernard, G. R., Chiche, J.-D., Coopersmith, C. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.0287 · Cited by 28,250
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Murray, C. J. L., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02724-0 · Cited by 16,316 · cited 1×
“This misuse jeopardizes individual health and overburdens national healthcare systems financially [23].”
BackgroundSurviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621 · cited 2×
“…administration and efficient source control [139], as validated by the inclusion of similar recommendations in 2016 SSC guidelines for early delivery of appropriate broad-spectrum antimicrobial drugs within one hour of hospital admission in patients afflicted by sepsis and septic shock [28,132].”
BackgroundTacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142 · cited 2×
“This has widened the gap between the urgent public health need for effective antibiotics and the diminishing prospects of developing new antibacterial medications, resulting in a concerning situation [19].”
BackgroundKumar, A., Roberts, D., Wood, K. E., Light, B., Parrillo, J. E., Sharma, S., Suppes, R., Feinstein, D., Zanotti, S., Taiberg, L., et al. (2006) · Critical Care Medicine · doi:10.1097/01.ccm.0000217961.75225.e9 · Cited by 6,109 · cited 2×
“In such conditions, each hour of delay in treatment worsens patient conditions and increases morbidity and mortality [87].”
BackgroundInfluentialThe epidemiology of sepsis in the United States from 1979 through 2000
Martin, G. S., Mannino, D. M., Eaton, S., & Moss, M. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022139 · Cited by 5,841 · cited 3×
“One study identified a higher incidence of sepsis among males than in fe-Antibiotics males [83].”
BackgroundAntibiotic resistance threats in the United States, 2019
(U.S.), C. F. D. C. A. P. (2019) · doi:10.15620/cdc:82532 · Cited by 5,782
Tong, S. Y. C., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015) · Clinical Microbiology Reviews · doi:10.1128/cmr.00134-14 · Cited by 5,192
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082 · cited 2×
“Due to increased prevalence and pathobiological, molecular, genomic, and medical complications, sepsis and septic shock pose a growing worldwide burden and a formidable challenge for emergency doctors [28].”
BackgroundFleischmann, C., Scherag, A., Adhikari, N. K. J., Hartog, C. S., Tsaganos, T., Schlattmann, P., Angus, D. C., & Reinhart, K. (2016) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0781oc · Cited by 3,548 · cited 2×
“According to a 2016 systematic review conducted in well-developed countries, over 30 million hospital-treated sepsis cases were reported annually worldwide, and 5.3 million individuals died from sepsis [31].”
BackgroundInfluentialLong-term cognitive impairment and functional disability among survivors of severe sepsis.
Iwashyna, T. J., Ely, E. W., Smith, D. M., & Langa, K. M. (2010) · JAMA · doi:10.1001/jama.2010.1553 · Cited by 2,582 · cited 1×
“For instance, older patients with sepsis may experience long-term severe health issues, such as cognitive impairment and functional disability [13].”
BackgroundAntimicrobial Resistance: Implications and Costs
Dadgostar, P. (2019) · Infection and Drug Resistance · doi:10.2147/idr.s234610 · Cited by 2,024 · cited 1×
“Hence, tackling AMR is a crucial aspect of ensuring safe and successful healthcare delivery, as highlighted by the implementation of ASP [196].”
BackgroundDerivation, Validation, and Potential Treatment Implications of Novel Clinical Phenotypes for Sepsis
Seymour, C. W., Kennedy, J. N., Wang, S., Chang, C.-C. H., Elliott, C. F., Xu, Z., Berry, S., Clermont, G., Cooper, G., Gomez, H., et al. (2019) · JAMA · doi:10.1001/jama.2019.5791 · Cited by 1,567
The timing of early antibiotics and hospital mortality in sepsis.
Liu, V. X., Fielding-Singh, V., Greene, J. D., Baker, J. M., Iwashyna, T. J., Bhattacharya, J., & Escobar, G. J. (2017) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201609-1848oc · Cited by 1,006
Horn, D. L., Neofytos, D., Anaissie, E. J., Fishman, J. A., Steinbach, W. J., Olyaei, A. J., Marr, K. A., Pfaller, M. A., Chang, C., & Webster, K. M. (2009) · Clinical Infectious Diseases · doi:10.1086/599039 · Cited by 956 · cited 1×
“Similarly, various published manuscripts have confirmed that male patients with candidemia have a higher risk of developing sepsis than females [77,78].”
BackgroundAntibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901 · cited 1×
“Indeed, inadequate antimicrobial therapy can have detrimental ecological effects on the microenvironment as it can cause superinfection with MDR pathogens [66].”
BackgroundWhat is antimicrobial stewardship?
Dyar, O. J., Huttner, B., Schouten, J., & Pulcini, C. (2017) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2017.08.026 · Cited by 870 · cited 1×
“…prevention and control (IPC) and medicine followed by patient safety are the other two principles of ASP, ASP cannot be successful without including IPC [186] because healthcare epidemiologists and infection preventionists play a pivotal role in the implementation and success of ASP [187].”
BackgroundSnitkin, E. S., Zelazny, A. M., Thomas, P. J., Stock, F., Program, N. C. S., Henderson, D. K., Palmore, T. N., & Segre, J. A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004129 · Cited by 863 · cited 1×
“…involvement of numerous medical team members and the utilization of numerous patient care devices for lifesaving critical care treatments may increase the chances of infection transmission from staff or fomites to outbreaks [207] or environments where high-concern pathogens are present [208].”
BackgroundSterling, S. A., Miller, W. R., Pryor, J., Puskarich, M. A., & Jones, A. E. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000001142 · Cited by 434 · cited 1×
“A meta-analysis comprising over 16,000 individuals with sepsis and septic shock from 11 studies identified an insignificant difference between antibiotic administration (within 3 h) and mortality rate [158].”
MethodThe global burden of sepsis: barriers and potential solutions
Rudd, K. E., Kissoon, N., Limmathurotsakul, D., Bory, S., Mutahunga, B., Seymour, C. W., Angus, D. C., & West, T. E. (2018) · Critical Care · doi:10.1186/s13054-018-2157-z · Cited by 416 · cited 1×
“Context-specific solutions to this serious problem are essential due to considerable disparities in susceptible populations, the infecting microorganisms, and the healthcare ability to manage sepsis globally, particularly in low and middle-income countries (LMIC) [223].”
BackgroundPuskarich, M. A., Trzeciak, S., Shapiro, N. I., Arnold, R. C., Horton, J. M., Studnek, J. R., Kline, J. A., & Jones, A. E. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e31821e87ab · Cited by 376 · cited 1×
“These studies have confirmed that appropriate antibiotic therapy significantly decreased the mortality rate when it was given within ≤ 1 h [33], whereas each hour of delay in the treatment increased mortality [150] and dropped the overall survival rate by an average of 7.6% [87].”
BackgroundInfluentialEpidemiology and Immune Pathogenesis of Viral Sepsis
Lin, G.-L., McGinley, J. P., Drysdale, S. B., & Pollard, A. J. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02147 · Cited by 351 · cited 1×
“However, this may become increasingly challenging due to the rising incidence of sepsis caused by unusual pathogens [93].”
BackgroundPrehospital antibiotics in the ambulance for sepsis: A multicentre, open label, randomised trial.
Alam, N., Oskam, E., Stassen, P. M., Exter, P. V., van de Ven, P. M., Haak, H. R., Holleman, F., Zanten, A. V., Leeuwen-Nguyen, H. V., Bon, V., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30469-1 · Cited by 290
Ljungström, L., Pernestig, A.-K., Jacobsson, G., Andersson, R., Usener, B., & Tilevik, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181704 · Cited by 219
Recommendations for sepsis management in resource-limited settings
Dünser, M. W., Festic, E., Dondorp, A., Kissoon, N., Ganbat, T., Kwizera, A., Haniffa, R., Baker, T., Schultz, M. J., & Global Intensive Care Working Group of the European Society of Intensive Care Medicine (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2468-5 · Cited by 176
Rello, J., van Engelen, T. S. R., Alp, E., Calandra, T., Cattoir, V., Kern, W. V., Netea, M. G., Nseir, S., Opal, S. M., van de Veerdonk, F. L., et al. (2018) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2018.03.011 · Cited by 143 · cited 1×
“Many other studies have identified that timely antibiotic treatment yields a lesser impact than the patient control group, indicating the variability of the disease and the necessity for continued analysis and medication [124,125].”
BackgroundLevy, M. M., Gesten, F. C., Phillips, G. S., Terry, K. M., Seymour, C. W., Prescott, H. C., Friedrich, M., Iwashyna, T. J., Osborn, T., & Lemeshow, S. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201712-2545oc · Cited by 137
Ong, D. S. Y., Frencken, J. F., Klein Klouwenberg, P. M. C., Juffermans, N., van der Poll, T., Bonten, M. J. M., & Cremer, O. L. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/cix186 · Cited by 109 · cited 1×
“Similar findings were reported in other studies where researchers linked higher mortality with nephrotoxic side effects leading to renal failure [166].”
ResultHospital-based acute care use in survivors of septic shock.
Ortego, A., Gaieski, D. F., Fuchs, B. D., Jones, T., Halpern, S. D., Small, D. S., Sante, S. C., Drumheller, B., Christie, J. D., & Mikkelsen, M. E. (2015) · Critical Care Medicine · doi:10.1097/ccm.0000000000000693 · Cited by 67
Metadata
- Authors
- Kumar, N. R., Balraj, T. A., Kempegowda, S. N., & Prashant, A.
- Venue
- Antibiotics
- Publisher
- MDPI AG
- Published
- 2024-01-04
- Volume
- 13
- Issue
- 1
- Pages
- 46
- ISSN
- 2079-6382 (ISSN-L)
- OpenAlex
- W4390588124
- Cited by
- 162
- References
- 30
- FWCI
- 42.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.